Navigation Links
Advanced Life Sciences Announces Outcome of FDA's Anti-Infective Drugs Advisory Committee Review of Restanza(TM) (cethromycin)
Date:6/2/2009

olides and penicillins are currently the front-line treatments for respiratory tract infections such as CAP. As macrolide and penicillin resistance grows and has the potential to cause more clinical failures, there is a need for new antibiotics with unique mechanisms of action that can overcome this emerging resistance.

About Advanced Life Sciences

Advanced Life Sciences is a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, cancer, respiratory diseases and biodefense. For more information, please visit us on the web at www.advancedlifesciences.com

Any statements contained in this press release that relate to future plans, events or performance are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of

1995. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, among others, those relating to technology and product development, market acceptance, government regulation and regulatory approval processes, intellectual property rights and litigation, dependence on collaborative relationships, ability to obtain financing, competitive products, industry trends and other risks identified in Advanced Life Sciences' filings with the Securities and Exchange Commission. Advanced Life Sciences undertakes no obligation to update or alter these forward-looking statements as a result of new information, future events or otherwise.


'/>"/>
SOURCE Advanced Life Sciences Holdings, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. PharmAthene Submits Proposal to BARDA in Response to Broad Agency Announcement for Advanced Research and Development for Valortim(R)
2. Medivation Announces Positive New Efficacy Data From Phase 1-2 Trial of MDV3100 in Advanced Prostate Cancer Patients
3. Keryx Biopharmaceuticals Announces Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
4. Entremed Presents Results of ENMD-2076 Phase 1 Study in Advanced Cancer Patients
5. Keryx Biopharmaceuticals Reports Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
6. Proteolix Presents Phase 1b/2 Clinical Data for Carfilzomib in Advanced Solid Tumor Patients at the 2009 ASCO Annual Meeting
7. Video: Phase III Study Data With Vandetanib (Zactima(TM)) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Presented at American Society of Clinical Oncology
8. Induction Chemotherapy Followed by ChemoRadiotherapy Increased Time-to-Treatment Failure Compared to ChemoRadiotherapy Alone in Patients With Unresectable Locally Advanced Head & Neck Cancer
9. Keryx Biopharmaceuticals Reports Single Agent Phase 2 Data of KRX-0401 (Perifosine) Further Demonstrating KRX-0401s Activity in the Treatment of Advanced Metastatic Renal Cell Cancer
10. New Preliminary Data from Two Studies Show Clinical Activity of Neratinib in Combination with Trastuzumab and in Combination with Paclitaxel in Advanced HER-2 Positive Breast Cancer
11. Celladon Provides MYDICAR(R) Program Update of First-In-Human Trial for Advanced Heart Failure at American Society of Gene Therapy Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... , July 25, 2014 Research and ... "Global Ophthalmic Diagnostic Devices Market 2014-2018" report to ... About Ophthalmic Diagnostic Device ... to identify a defect or deficiency in the human ... ophthalmic disorders such as presbyopia, cataracts, glaucoma, retinal disorders, ...
(Date:7/25/2014)... , July 25, 2014 Leading events ... is returning for the seventh year to São Paulo, ... th August 2014. The event will co-locate with Food ... most comprehensive meeting point for the pharmaceutical industry. ... 25 countries for pharmaceutical sales are now exploring the ...
(Date:7/24/2014)... Calif. , July 24, 2014   AcelRx ... pharmaceutical company focused on the development and commercialization of ... pain, today confirmed the PDUFA date for Zalviso remains ... that a rumor circulated online stating the Food and ... 24, 2014 there has been no notification to the ...
Breaking Medicine Technology:Global Ophthalmic Diagnostic Devices Market 2014-2018: Key Vendors are Alcon, Carl Zeiss, Haag-Streit and Topcon 2CPhI South America 2014 Launches with Generics Showing Huge Growth 2CPhI South America 2014 Launches with Generics Showing Huge Growth 3CPhI South America 2014 Launches with Generics Showing Huge Growth 4AcelRx Pharmaceuticals Confirms July 27, 2014 PDUFA Date for Zalviso 2
... BOSTON, Dec. 9 Solos Endoscopy, Inc. (Pink Sheets: SNDY) ... sales for the month of October 2009 and $42,898.42 in ... October 2008 and $32,028.52 for November 2008 respectively. , About ... instrument company whose mission is to develop and market breakthrough ...
... , , , GAITHERSBURG, Md, ... in the development and manufacture of lentiviral gene delivery ... Institutes of Health (NIH) small business innovation research (SBIR) ... Generating Hepatitis C Virus-Like Particles using Lentivirus". In ...
Cached Medicine Technology:Lentigen Awarded Phase I SBIR Grant for Hepatitis C Vaccine 2
(Date:7/27/2014)... of Manchester have discovered why medication to treat asthma and ... Nature Medicine , show that drugs widely used to treat ... In the UK pneumonia, which is caused by an infection, ... more serious for babies, young children, the elderly, smokers and ... 5 million people in the UK are affected by asthma ...
(Date:7/27/2014)... Over the past five years, the ... thanks to many consumers valuing the taste and versatility ... Association of Canada's Canadian Coffee Drinking Study in 2011 ... per day. “This trend, coupled with many studies that ... tea on a daily basis, has stimulated consumer demand ...
(Date:7/27/2014)... The report, “Oil Filter & Fuel ... HCVs), Market Type (OE & Aftermarket), Filter Type (Oil ... - Industry Trends & Forecast to 2018”, defines and ... with analysis and forecasting of the global volume and ... to reach a revenue of $6.1 billion in 2018, ...
(Date:7/27/2014)... 1-Butene is a colorless, combustible gas with a ... be manufactured either through the separation from crude C4 ... alpha olefin (alkene) 1-Butene is a versatile chemical that ... chemicals such as linear light density polyethylene (LLDP), polybutene-1, ... market is extremely competitive. The market has several market ...
(Date:7/27/2014)... (PRWEB) July 27, 2014 Metachromatic ... a lysosomal storage disease which is commonly listed ... among the sphingolipidoses as it affects the metabolism ... of myelin, the fatty covering which acts as ... and peripheral nervous systems. MLD involves cerebroside sulfate ...
Breaking Medicine News(10 mins):Health News:Drugs used to treat lung disease work with the body clock 2Health News:Coffee and Tea Production in Canada Industry Market Research Report Now Available from IBISWorld 2Health News:Coffee and Tea Production in Canada Industry Market Research Report Now Available from IBISWorld 3Health News:Oil Filter & Fuel Filter Market Worth $18.6 Billion by 2018 - Report by MarketsandMarkets 2Health News:Oil Filter & Fuel Filter Market Worth $18.6 Billion by 2018 - Report by MarketsandMarkets 3Health News:Oil Filter & Fuel Filter Market Worth $18.6 Billion by 2018 - Report by MarketsandMarkets 4Health News:Oil Filter & Fuel Filter Market Worth $18.6 Billion by 2018 - Report by MarketsandMarkets 5Health News:North America 1-Butene Market is Expected to Reach $794 million in 2018 - New Report by MicroMarket Monitor 2Health News:North America 1-Butene Market is Expected to Reach $794 million in 2018 - New Report by MicroMarket Monitor 3Health News:North America 1-Butene Market is Expected to Reach $794 million in 2018 - New Report by MicroMarket Monitor 4Health News:Metachromatic Leukodystrophy Therapeutics Clinical Trials Market Review H2 2014 Report Available at LifeScienceIndustryResearch.com 2Health News:Metachromatic Leukodystrophy Therapeutics Clinical Trials Market Review H2 2014 Report Available at LifeScienceIndustryResearch.com 3Health News:Metachromatic Leukodystrophy Therapeutics Clinical Trials Market Review H2 2014 Report Available at LifeScienceIndustryResearch.com 4Health News:Metachromatic Leukodystrophy Therapeutics Clinical Trials Market Review H2 2014 Report Available at LifeScienceIndustryResearch.com 5
... 13 Berkery Noyes announced today that,the firm represented ... HCPro Holdings, Inc. to Halyard Capital. The management team ... Terms of the transaction,were not disclosed., "This is ... team with a winning healthcare and information franchise," said,Tom ...
... with glasses brought them up to snuff with ... News) -- Preschoolers with poor vision significantly improved ... wearing prescription glasses, a new study shows. , ... have early vision problems that are undiagnosed and ...
... Inc.,(Nasdaq: TSTF ), a national provider of ... has hired Jeff Davis as Director,of Operations for ... will be responsible for leading client field,operations and ... existing and new contracts. Mr. Davis will report ...
... Healthcare Industry to Follow Suit, WASHINGTON, Feb. ... to require all of its administrative,data-exchange vendors to ... Committee on Operating Rules for Information Exchange (CORE), ... electronic administrative data,exchange," said Ronald A. Williams, CAQH ...
... healthcare privacy auditing solutions, ... titled Addressing Electronic Health Record Privacy and ... HIMSS Chairman & Vice ... Robert Sullivan of PricewaterhouseCoopers, Healthcare Advisory ...
... Enters Into Marketing Partnership for Once-Daily Tramadol for ... ... Feb. 13 /PRNewswire-FirstCall/ - Labopharm Inc. (TSX: DDS;,NASDAQ: DDSS) today announced ... Food and Drug Administration,which allows for the marketing and sale of ...
Cached Medicine News:Health News:Berkery Noyes Represented The Riverside Company on the Sale of HCPro Holdings, Inc. to Halyard Capital, LLC 2Health News:Berkery Noyes Represented The Riverside Company on the Sale of HCPro Holdings, Inc. to Halyard Capital, LLC 3Health News:Fixing Poor Vision Boosts Preschoolers' Test Scores 2Health News:TeamStaff Hires Jeff Davis as Director of Operations for Government Solutions Subsidiary 2Health News:TeamStaff Hires Jeff Davis as Director of Operations for Government Solutions Subsidiary 3Health News:Aetna Requires CAQH Core Rules Certification for Vendors 2Health News:Aetna Requires CAQH Core Rules Certification for Vendors 3Health News:FairWarning to Host Webinar Featuring HIMSS Chairman and Healthcare Executive from PricewaterhouseCoopers on Electronic Health Record Privacy and Compliance Challenges 2Health News:Labopharm's Once-Daily Tramadol Approved in South Korea and Australia 2Health News:Labopharm's Once-Daily Tramadol Approved in South Korea and Australia 3
... Pro Osteon Bone Graft Substitutes a natural ... from cadaver bone, but such grafts may ... disease transmission. Interpore Cross has developed the ... to address these needs, offering surgeons a ...
... osteoconductive matrix constructed of cross-linked collagen ... hydroxyapatite through a proprietary 360 accretion ... marrow aspirate, Healos provides an excellent ... and differentiation. The hydroxyapatite-coated collagen microfibers ...
Weitlaner-Locktite retractors, blunt, 11 cm total length....
Sharp Weitlaner Retractor....
Medicine Products: